The Pharma Data

SEPTEMBER 10, 2020

The disruption to hospitals in England during the pandemic has meant the number of patients facing long waits for routine operations has soared. But there are some encouraging signs, with treatments happening in hospitals on the increase. Image copyright. Getty Images. The numbers coming to Accident and Emergency topped 1.7m

Hospitals 52

Hospitals Treatment Virus 52

The Pharma Data

NOVEMBER 10, 2020

Antibody Treatment Approved for Emergency Use Against Early COVID-19. 10, 2020 — Eli Lilly’s experimental antibody treatment for COVID-19 was given emergency approval by the U.S. ” The agency warned that it should not be used in patients who are already hospitalized with the illness. Professional. government.

Treatment 52

Treatment Government Hospitals FDA 52

The Pharma Data

OCTOBER 22, 2020

FDA Approves Veklury (remdesivir) for the Treatment of COVID-19. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. As an antiviral drug, Veklury works to stop replication of SARS-CoV-2, the virus that causes COVID-19.

FDA Approval 52

FDA Approval Treatment FDA Hospitals 52

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. This press release features multimedia.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

OCTOBER 30, 2020

NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. About the REGN-COV2 Trial in Hospitalized Patients. Regeneron Pharmaceuticals, Inc.

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

DECEMBER 20, 2020

20 , 2020 /PRNewswire/ — The broad spectrum antiviral therapeutic, ‘hzVSF-v13(humanized Virus Suppressing Factor)’ being developed by ImmuneMed , is on track to progress as a treatment for the COVID-19 pneumonia patients. CHUNCHEON, South Korea , Dec. Media Contact.

Clinical Trials 40

Clinical Trials Treatment Trials Hospitals 40

The Pharma Data

SEPTEMBER 7, 2020

‘I just want my life back’ The government moved away from community testing on 12 March, instead only testing those admitted to hospital. However, many of these people may not have been tested for Covid. That meant people who recovered from suspected coronavirus at home were unable to access tests. ” Person-centred rehab.

Doctors 52

Doctors Treatment Hospitals Government 52

The Pharma Data

SEPTEMBER 28, 2020

The NHS is facing a “triple whammy” of rising Covid-19 cases, a major backlog in treatment and reduced capacity due to infection-control measures, according to health bosses. The NHS bosses also called on ministers to be “honest and realistic” about waiting lists for treatment.

Nurses 52

Nurses Virus Hospitals Treatment 52

The Pharma Data

JANUARY 21, 2021

Senhwa’s Silmitasertib is an oral medication, targeting the host protein kinase CK2 (casein kinase 2), where virus mutations are unlikely to affect its anti-viral and anti-inflammatory efficacy. It is thought that Silmitasertib challenges the virus’ ability to replicate quickly and spread to nearby healthy cells.

Trials 40

Trials Treatment Small Molecule Hospitals 40

DrugBank

JUNE 13, 2024

These innovative technologies are changing how medications reach their targets within the body, leading to more effective treatments with fewer side effects.   Take cancer treatment, for example. Implantable insulin pumps equipped with continuous glucose monitoring (CGM) sensors can update old diabetes treatment options.

Therapies 98

Therapies Drugs DNA Treatment 98

Broad Institute

MAY 30, 2023

She realized the importance of her role in keeping the worms healthy, so she could later study their gene expression and behavior in response to different drug treatments. I love working on medical samples that are provided by patients because it motivates me to find them an answer or even a potential treatment.

Research 89

Research Medical Schools Doctors Science 89

The Pharma Data

NOVEMBER 5, 2020

Regeneron announced today an update from the independent data monitoring committee (DMC) for the United Kingdom-based RECOVERY trial evaluating REGN-COV2 in hospitalized patients with COVID-19.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

OCTOBER 28, 2020

REGN-COV2 significantly reduced viral load and patient medical visits (hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits). In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 There was a 1.08 placebo; p=0.024).

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

AUGUST 13, 2020

Piyush Madhani decided to take part in the study “to contribute to the understanding and cure of this virus” A man who had Covid-19 has become the first to take part in what is thought to be the UK’s largest study into how the virus affects people after they leave hospital. It has been granted £8.4m

Virus 52

Virus Hospitals Research Treatment 52

The Pharma Data

AUGUST 11, 2020

The treatment is already available on an emergency basis for people suffering with severe symptoms from coronavirus. It has not received general approval to treat the virus in the US, but has in several European countries and Japan. Gilead Sciences has asked the FDA to approve its drug remdesivir to treat COVID-19 patients.

FDA Approval 52

FDA Approval FDA Government Virus 52

The Pharma Data

AUGUST 3, 2020

Although there is still much that doctors don’t know about how pregnancy can be affected by the virus, pregnant women do not appear to become more unwell than other healthy adults who contract it. Can I pass the virus to my baby during pregnancy? But what do we know about its impact on pregnancy? What did recent UK research find?

Virus 52

Virus Hospitals Doctors Treatment 52

The Pharma Data

OCTOBER 26, 2020

Hasan Jafri , Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.” ” Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus Date: Wednesday, October 28, 2020 Time: 10:30AM- 11:50AM ET.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

Nvidia Developer: Drug Discovery

OCTOBER 5, 2021

Recently published in the Proceedings of the National Academy of Sciences , the research develops a deep learning model that determines the best drug combinations for fighting the virus, despite having relatively limited data. But there’s little clarity around optimal treatment combinations, while also limiting possible side effects.

Drugs 52

Drugs Virus Science Disease 52

The Pharma Data

DECEMBER 3, 2020

The changes help the virus to multiply and eventually destroy the cells. Kidney Disease Leading Risk Factor for COVID-related Hospitalization. Investigators analyzed Geisinger Health System ’s electronic health records and found that chronic kidney disease is the leading risk factor for COVID-19 hospitalization. Source link.

Disease 52

Disease Research Virus Hospitals 52

The Pharma Data

JULY 12, 2021

The Phase 3 portion of the global MOVe-OUT trial studying molnupiravir in non-hospitalized adult patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes is underway. This press release features multimedia. View the full release here: [link]. “It

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

The Pharma Data

DECEMBER 21, 2020

(Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. It is in advanced development for the treatment of Marburg virus disease.

Clinical Trials 52

Clinical Trials Virus RNA Trials 52

The Pharma Data

AUGUST 7, 2020

NHS England has announced it is to end the deal that gave it access to more than 90% of private hospitals’ beds, staff and equipment. Doctors’ bodies have stressed the need to make sure the NHS can access beds, with millions waiting for treatment. NHS England said it would still fund local spending on private hospitals.

Hospitals 52

Hospitals Doctors Virus Government 52

The Pharma Data

JANUARY 21, 2021

Researchers randomized patients to either 4,200 mg of IV-administered bamlanivimab or placebo and saw that after eight weeks of participant follow-up, the 965 participants who tested negative for the virus at baseline saw a 57 percent lower frequency of symptomatic COVID-19 in the drug arm compared to the placebo arm. James Miessler.

Nurses 52

Nurses Research Laboratories Laboratories Virus 52

The Pharma Data

SEPTEMBER 9, 2020

But at the start of the pandemic, the UK was only largely able to test hospital patients. It means we are able to look more closely for virus circulating in the community than we were when mass testing first started. Hospital admissions aren’t rising as much as cases. There was limited testing capacity. Source link.

Hospitals 52

Hospitals Virus Government Treatment 52

The Pharma Data

OCTOBER 27, 2021

The research opens up the possibility for the development of passive immunization or treatment against SARS-CoV-2 infection. The technique combines the advantages of using an antigen that closely resembles its state on the surface of the native virus with the biosafety advantages related to using a recombinant immunogen. 2 variants.

Clinical Trials 52

Clinical Trials Virus Production Treatment 52

The Pharma Data

AUGUST 30, 2021

Pulmonary infection with the SARS-CoV2 virus can progress to acute respiratory distress syndrome (ARDS), in which inflammation and neutrophil hyperactivation play a central role. Given the central role played by neutrophils in ARDS, the team postulated that metoprolol might be an effective treatment for patients with severe COVID-19.

Clinical Trials 52

Clinical Trials Drugs Trials Hospitals 52

The Pharma Data

MARCH 2, 2021

Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s HIV, hepatitis C virus (HCV), and COVID-19 research and development programs at the 28th Conference on Retroviruses and Opportunistic Infections ( virtual CROI 2021) taking place from March 6-10. Gilead Sciences, Inc. HCV Research. COVID-19 Research.

Virus 40

Virus Treatment Science Trials 40

The Pharma Data

NOVEMBER 23, 2020

23, 2020 — Fresh takes on the efficacy of fish oil and vitamin D, new treatments for heart failure patients, the cardiovascular effects of COVID-19 , and structural racism as a driver of health disparity were just a few of the major developments that emerged from the American Heart Association Scientific Sessions 2020, held virtually from Nov.

Research 52

Research Virus Therapies Trials 52

The Pharma Data

DECEMBER 4, 2020

Boston Children’s Hospital’s emergency department (ED) observed a steep decline in asthma-related emergency visits last spring. The number of hospital admissions for asthma also declined, while the proportion of asthma-related emergency visits that required hospitalization remained similar to previous years.

Hospitals 52

Hospitals Doctors Virus Treatment 52

The Pharma Data

APRIL 3, 2021

The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints. About the ITAC Trial.

Clinical Trials 52

Clinical Trials Trials Hospitals Treatment 52

NIH Director's Blog: Drug Development

OCTOBER 27, 2020

Another promising strategy is drugs that target the proteins within human cells that the virus needs to infect, multiply, and spread. These studies narrowed the list to 73 human proteins that the virus depends on to replicate. That’s the strategy employed by remdesivir , the only antiviral drug currently authorized by the U.S.

Drug Development 52

Drug Development Drugs Virus Science 52

The Pharma Data

FEBRUARY 23, 2022

. * In the VAT08 Phase 3 primary series trial, two doses of the Sanofi-GSK vaccine in seronegative populations demonstrated: * 100% efficacy against severe COVID-19 disease and hospitalizations * 75% efficacy against moderate or severe COVID-19 disease * 57.9% Favorable safety profile following both primary series and booster vaccinations.

Vaccine 52

Vaccine Virus Trials Immune Response 52

NIH Director's Blog: Drug Development

APRIL 2, 2020

ACE2 is the receptor that the virus uses to gain entry. Solomon of Brigham and Women’s Hospital and Harvard Medical School, Boston, found that current evidence in humans is insufficient to support or refute claims that ACE inhibitors or ARBs may be helpful or harmful to individuals with COVID-19. The team, led by Scott D.

Drug Development 52

Drug Development Drugs Science Medical Schools 52

Common Sense for Drug Policy Blog

JANUARY 1, 2024

18 The average cost of a hepatitis A–related hospitalization in 2016 was $16 610, and recent hepatitis A virus outbreaks alone have cost the nation at least $270 million since 2016. 19 In 2019, HIV care and treatment cost the US government more than $20 billion.

Virus 40

Virus Government Hospitals Treatment 40

The Pharma Data

JUNE 26, 2021

The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or protein degradation.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Agency IQ

SEPTEMBER 6, 2023

The Antimicrobial Testing Program (ATP) ensures that EPA-approved hospital disinfectants, sterilants, and tuberulocidal products in the marketplace meet stringent efficacy standards. Commenters also provided edits to both the virus and bacterial methods, as well as the claim and use sites.

Production 40

Production Virus Long-Term Care Facilities Laboratories 40